Sociodemographic, Clinical, and Pathological Factors Influencing Outcomes in Locally Advanced Triple Negative Breast Cancer: A Brazilian Cohort

Silva, Jessé Lopes da; Paula, Bruno de; Small, I. A.; Thuler, Luiz Cláudio Santos; Melo, Andréia Cristina de

doi:10.1177/1178223420962488

Cited by 4 publications

(6 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the literature indicates that there is no relationship between alcohol dependence and increased risk of TNBC 14 . Alcohol dependence is also associated with a worse chemotherapy response (first-line treatment for TNBC), worsening survival in these cases 15 . Alcohol-dependent patients in this study did not show a worse OS and/or DFS and an increased risk of mortality and/or recurrence.…”

Section: Discussionmentioning

confidence: 99%

Prognostic factors in triple-negative breast cancer: a retrospective cohort

Costa

Oliveira

Araújo³

et al. 2021

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

OBJECTIVE: Triple-negative breast cancer (TNBC) is characterized by lack of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) expression and accounts for 15-20% of all breast cancers. This study aims to analyze prognostic factors related to a reduction in overall survival (OS), disease-free survival (DFS), and risk of mortality and recurrence in TNBC.METHODS: This is a retrospective observational cohort study. Medical records of 532 patients with breast cancer diagnosed from 2007 to 2020 were analyzed. Of these patients, 93 (17%) were women with TNBC. Ten medical records were excluded, and the final sample was composed of 83 women with TNBC. OS and DFS were estimated by the Kaplan-Meier model. Univariate analysis (log-rank test) and multivariate analysis (Cox regression) were used to examine prognostic factors related to a statistically significant reduction (p<0.05) in OS and DFS and increased risk of mortality and tumor recurrence.RESULTS: Smoking, advanced clinical stage, larger tumor size, angiolymphatic invasion, positive sentinel lymph node, axillary node involvement, higher cancer burden, surgical treatment with mastectomy, and recurrence were related to a significant decrease in OS and/or DFS and increased risk of mortality and/or recurrence in TNBC. The 10-year OS and DFS was around 61 and 65%, respectively. CONCLUSIONS: Advanced clinical stage, positive sentinel lymph node, axillary node involvement, surgical treatment with mastectomy, and higher residual cancer burden were related to a significant reduction in OS and DFS and increased risk of mortality and recurrence in TNBC.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic factors in triple-negative breast cancer: a retrospective cohort

Costa

Oliveira

Araújo³

et al. 2021

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

show abstract

“…These patients also exhibited a high prevalence rate of obesity, higher Ki67 score, as well as LVI and PNI, all of which are traditional prognostic factors for poorer outcomes in breast cancer patients. 23,24 Additionally, RCB, an outcome used to determine the volume of residual disease after NACT with well-known strong impact on patient survival, displayed similar proportions among HER2 subgroups. 25 That said, the pattern of response to NACT in patients with TNBC might be independent of HER2 expression status by IHC.…”

Section: Discussionmentioning

confidence: 89%

Exploring Real-World HER2-Low Data in Early-Stage Triple-Negative Breast Cancer: Insights and Implications

da Silva,

Carvalho,

Zanetti de Albuquerque

et al. 2023

BCTT

Self Cite

View full text Add to dashboard Cite

This study aimed to compare the clinical behavior, clinicopathological and sociodemographic characteristics of patients with early-stage triple-negative breast cancer (TNBC) who belong to the HER2-low and HER2-zero subgroups. Patients and Methods: This study involved a thorough search in the internal database of a single Brazilian institution to identify women with TNBC who underwent neoadjuvant chemotherapy (NACT) followed by curative surgery within the period from January 2010 to December 2014. HER2 analysis through immunohistochemistry (IHC) and, if required, amplification by in situ hybridization, was conducted using core biopsy samples. The study assesses outcomes of residual cancer burden (RCB), event-free survival (EFS), and overall survival (OS). Results: A total of 170 cases were analyzed, with a mean age of 51.4 years (standard deviation, SD 11.2). The HER2 status was categorized as IHC 0, 1+, or 2+ in 80 (47.1%), 73 (42.9%), and 17 (10%) patients, respectively. No significant differences were observed in the prevalence of clinical pathological characteristics among the subgroups. The absence of significant results for clinicopathological and demographic features hindered the multivariate analysis of HER2 subgroups. Similarly, no significant differences were found in the RCB, EFS, and OS outcomes between HER2 subgroups. Conclusion:The findings of this study suggest that, in early-stage TNBC, the clinical behavior and survival outcomes of the HER2low subgroup may not differ significantly from those of the HER2-zero subgroup.

show abstract

“…Although several studies indicate that the addition of platinum drugs to the neoadjuvant regimens could increase pathological complete response 35 , 36 , few patients were treated with such drugs during the time range evaluated in this study period (2014–2017). For patients receiving NAT, Silva et al reported that the most common regimens used are AC-T and FAC-T (fluorouracil plus doxorubicin plus cyclophosphamide followed by docetaxel) 13 . Herein, we also observed AC-T as the main combination regimen in the neoadjuvant setting.…”

Section: Discussionmentioning

confidence: 99%

“…In Brazil, TNBC is most detected in stage III, with lymphocytic infiltration, multifocality, and tumor size > 2 cm at diagnosis 12 , 13 . Compared to other BC subtypes, a higher proportion of patients with TNBC undergo radical surgery and chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

“…Compared to other BC subtypes, a higher proportion of patients with TNBC undergo radical surgery and chemotherapy. Most patients treated with NAT receive anthracycline followed by taxane regimens 13 , 14 . Overall survival of Brazilian TNBC patients tends to be lower than that observed worldwide, mainly due to late diagnosis and difficult access to healthcare services 12 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Treatment patterns and healthcare resource utilization for triple negative breast cancer in the Brazilian private healthcare system: a database study

Carlos Souto Maior Borba,

de Mendonça Batista,

Falcão Almeida

et al. 2023

Sci Rep

View full text Add to dashboard Cite

In Brazil, data on the management of triple negative breast cancer (TNBC) as well as the burden of the disease in terms of health care resources utilization (HCRU) are scarce. To characterize the treatment patterns and HCRU associated with the management of Brazilian TNBC patients from the perspective of the private healthcare setting. Patients with at least one claim related to ICD-10 C50 from January 2012 until December 2017, and at least one claim for breast cancer treatment were assessed from a private claims database and classified as early and locally advanced, or metastatic. All patients with hormone and/or targeted therapy were excluded. Three thousand and four patients were identified, of which 82.8% were diagnosed in early and locally advanced stages. For early and locally advanced TNBC patients, 75.3% were treated in an adjuvant setting, mainly with anthracycline regimes. For mTNBC patients, bevacizumab regimens were the main treatment prescribed. More than 48% of mTNBC patients were switched to a second line of treatment. HCRU was higher for mTNBC patients when compared to early and locally advanced patients, with higher costs for metastatic disease management. The treatment setting has little influence on the HCRU pattern or the cost of disease management. The highest burden of disease was observed for metastatic management.

show abstract

Sociodemographic, Clinical, and Pathological Factors Influencing Outcomes in Locally Advanced Triple Negative Breast Cancer: A Brazilian Cohort

Cited by 4 publications

References 79 publications

Prognostic factors in triple-negative breast cancer: a retrospective cohort

Prognostic factors in triple-negative breast cancer: a retrospective cohort

Exploring Real-World HER2-Low Data in Early-Stage Triple-Negative Breast Cancer: Insights and Implications

Treatment patterns and healthcare resource utilization for triple negative breast cancer in the Brazilian private healthcare system: a database study

Contact Info

Product

Resources

About